taletrectinib adipate · Nuvation · NDA 219713
Ibtrozi
Earliest generic entry, as listed
3 Jun 2033
Blocked by patent: US 9187489, US 9751887.
Listed patents · 2 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 9187489 | substance, product, use U-4207 | 3 Jun 2033 |
| US 9751887 | substance, product, use U-4207 | 3 Jun 2033 |
Exclusivities · 2 unexpired
| ODE-544 | orphan drug (7 years) | 11 Jun 2032 |
| NCE | new chemical entity (5 years) | 11 Jun 2030 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 219713 · 001 · RLD | capsule, oral | EQ 200MG BASE | 3 Jun 2033 |